Osteolytic lesions marker in multiple myeloma.
Irena Djunic1, Ivo Elezovic, Milica Marinkovic
1Institute of Hematology, Clinical Center of Serbia, str Koste Todorovica 2, Belgrade, Serbia. irenadju@eunet.rs
Medical Oncology (Northwood, London, England)
|February 4, 2010
Summary
Collagen type I carboxy terminal telopeptide (ICTP) serum levels significantly predict osteolysis in multiple myeloma (MM) patients. ICTP aids in identifying MM patients at higher risk for developing bone lesions.
Area of Science:
- Biochemistry
- Oncology
- Skeletal Biology
Background:
- Multiple myeloma (MM) frequently affects the skeleton.
- Osteolysis is a key characteristic of skeletal involvement in MM.
- Biochemical markers are needed to predict skeletal changes.
Purpose of the Study:
- To evaluate the significance of ICTP as an osteolysis predictor in MM.
- To compare ICTP's prognostic value with standard parameters like β(2)-microglobulin and CRP.
- To assess ICTP's role in predicting overall survival in MM patients.
Main Methods:
- Serum ICTP levels were measured in MM patients.
- Comparison of ICTP levels between patients with and without osteolytic lesions on radiography.
- Statistical analysis to determine the significance of ICTP, β(2)-microglobulin, and CRP as predictors of osteolysis and overall survival.
Main Results:
- A significant difference in serum ICTP levels was observed between MM patients with and without osteolysis (P = 0.009).
- ICTP was identified as the most significant predictor of osteolysis (P = 0.09).
- C-reactive protein (CRP) was the most significant risk factor for overall survival (P < 0.01).
Conclusions:
- Serum ICTP is a significant predictor of osteolysis in multiple myeloma.
- ICTP can identify MM patients at increased risk for osteolytic bone lesions.
- While CRP is crucial for survival prediction, ICTP offers valuable insights into skeletal disease progression.
